X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Wockhardt: Awaiting a trigger - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Sep 18, 2000

    Wockhardt: Awaiting a trigger

    Wockhardt’s stock price has seen a dip of over 10% over the past quarter despite the company successfully launching its biotech based Hepatitis–B vaccine, integrating Merind’s operations and having six pharmaceutical brands in the ORG Top–300. (Dexolac, the company’s medical nutrition brand was the new entrant to the ORG Top 300 in the first half.)

    Biovac–B, is reportedly giving a tough time to Engerix, SmithKline Pharma’s Hep–B vaccine having already sold a million doses (both paediatric and adult doses). Besides, the company has another biotech product erythoproetin (for the treatment of anaemia) slated for launch in the current year.

    Even in anti–infectives (which contributes almost 29% of the company’s turnover) Wockhardt has launched Floxur (a quinolone antibiotic) which is targeting a Rs 510 m market growing at over 40% per annum.

    Another promising business for the company is the infant nutrition business where its Dexolac brand registered a 33% growth in the first half.

    Business wise performance
    Business 1H June 2000 1H June 1999 Growth
    Pharma -Branded 1491 1325 13.0%
    Medical Nutrition 167 122 37.0%
    Pharma -Generics 102 177 -42.0%
    Bulk Drugs -Domestic 139 193 -28.0%
    Exports 527 436 21.0%
    Veterinary 209 100 110.0%
    Discontinued Products 0 118  
    Total 2636 2471* 7.0%
    *Includes Merind

    The key driver for Wockhardt stock from here on would be its success in the US generic market where it has filed seven patents already for NDDS already. The company already has a tie up with Sidmak Labs USA for distribution in place. It launched enalapril maleate (a cardiovascular formulation) tablets in the US generic market a month back, after the expiry of Merck’s patent.

    The company is among the highest spenders on R & D and spends anywhere between Rs 400 m to Rs 450 m on R & D every year, it amortises over a period of three years. It is also estimated to clock exports of a Rs 1 bn in the current year.

    We expect the company to report a net profit in the range of Rs 800 m (EPS: Rs 22.6) in the current year (the company accounting year ends in December) which implies an earnings multiple of less than 18 times.

     

     

    Equitymaster requests your view! Post a comment on "Wockhardt: Awaiting a trigger". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    WOCKHARDT LTD. SHARE PRICE


    Aug 21, 2017 11:15 AM

    TRACK WOCKHARDT LTD.

    • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON WOCKHARDT LTD.

    WOCKHARDT LTD. 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE WOCKHARDT LTD. WITH

    MARKET STATS